Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 26, Issue 20, 2008, Pages 3418-3425

  Schilder, Russell J ^a   Sill, Michael W ^a   Lee, Roger B ^a   Shaw, Tanya J ^a   Senterman, Mary K ^a   Klein Szanto, Andres J ^a   Miner, Zoe ^a   Vanderhyden, Barbara C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B BETA; STEM CELL FACTOR; VASCULOTROPIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ALLERGY; ANEMIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RECURRENT CANCER; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADULT; AGED; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROBABILITY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PIPERAZINES; PROBABILITY; PYRIMIDINES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 49149108140     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3420     Document Type: Article

References (62)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2007
2. Ozols RF, Rubin SC, Thomas GM, et al: Epithelial ovarian cancer, in Hoskins WJ, Young RC, Markman M, et al (eds): Principles and Practice of Gynecologic Oncology (ed 4). Lippincott Williams & Wilkins, Philadelphia, 2005, p 895
3. Wang C, Curtis JE, Geissler EN, et al: The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3:699-702, 1989
4. Ikeda H, Kanakura Y, Tamaki T, et al: Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78:2962-2968, 1991
5. Hines SJ, Organ C, Kornstein MJ, et al: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 6:769-779, 1995
6. Hibi K, Takahashi T, Sekido Y, et al: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6:2291-2296, 1991
7. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56:370-376, 1996
8. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998
9. Tonary AM, Macdonald EA, Faught W, et al: Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 89:242-250, 2000
10. Parrott JA, Mosher R, Kim G, et al: Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells. Endocrinology 141:2532-2539, 2000
11. Parrott JA, Kim G, Skiller MK: Expression and action of kit ligand stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod 62:1600-1609, 2000
12. Schmandt RE, Broaddus R, Lu KH, et al: Expression of c-abl, c-kit, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98:758-764, 2003
13. de Silva CM, Reid R: Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 9:13-19, 2003
14. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
15. Singer G, Schraml P, Belgard C, et al: KIT in ovarian carcinoma: Disillusion about a potential therapeutic target. J Natl Cancer Inst 95:1009-1010, 2003
16. Wilczynski SP, Chen YY, Chen W, et al: Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36:242-249, 2005
17. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet derived growth factor. Physiol Rev 79:1283-1316, 1999
18. Henriksen R, Funa K, Wilander E, et al: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554, 1993
19. Matei D, Emerson RE, Lai Y-C, et al: Autocrine activation of PDGFRa promotes the progression of ovarian cancer. Oncogene 25:2060-2069, 2006
20. Matei D, Sanchez K, Kelley M, et al: PDGFR A is overexpressed in ovarian carcinomas and represents a potential therapeutic target. Proc Am Soc Clin Oncol 22:867, 2003 (abstr 3485)
21. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
22. Carroll M, Ohno-Jones S, Tamura S, et al: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952, 1997
23. Druker BJ, Taipaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
24. Matei D, Chang DD, Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10:681-690, 2004
25. Shaw TJ, Vanderhyden BC: AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol Oncol 105:122-131, 2007
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
28. Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 1741-1744, 2002
29. Chen TT, Ng TH: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998
30. Schilder R, Sill M, Chen X, et al: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A gynecologic oncology group study. Clin Cancer Res 11:5539-5548, 2005
31. Collett D: Modelling Survival Data in Medical Research (ed 2). Boca Raton, FL, Chapman & Hall/ CRC, 2003, pp 116-117
32. Dziba JM, Ain KB: Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89:2127-2135, 2004
33. Krug LM, Crapanzano JP, Azzoli CG, et al: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial. Cancer 103:2128-2131, 2005
34. Posadas EM, Hussain MM, Espina V, et al: A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC). J Clin Oncol 22:872s, 2004 (suppl; abstr 9651)
35. Coleman RL, Broaddus RR, Bodurka DC, et al: Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101:126-131, 2006
36. Borgström P, Hillan KJ, Sriramarao P, et al: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039, 1996
37. Mu J, Abe Y, Tsutsui T, et al: Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 87:963-971, 1996
38. Abu-Jawdeh GM, Faix JD, Niloff J, et al: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74:1105-1115, 1996
39. Raspollini MR, Amunni G, Villanucci A, et al: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14:815-823, 2004
40. Goodheart MJ, Ritchie JM, Rose SL, et al: The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11:3733-3742, 2005
41. Tempfer C, Obermair A, Hefler L, et al: Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92:360-363, 1998
42. Gadducci A, Ferdeghini M, Fanucchi A, et al: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome. Anticancer Res 19:1401-1405, 1999
43. Chen CA, Cheng WF, Lee CN, et al: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival. Gynecol Oncol 74:235-240, 1999
44. Oehler MK, Caffier H: Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20:5109-5112, 2000
45. Hefler LA, Zeillinger R, Grimm C, et al: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 103:512-517, 2006
46. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560-10564, 1995
47. Kim DJ, Lee MH, Park TI, et al: Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci 21:81-85, 2006
48. Tallquist M, Kazlauskas A: PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205-213, 2004
49. Hong L, Munugalavadla V, Kapur R: C-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways. Mol Cell Biol 24:1401-1410, 2004
50. Song G, Ouyang G, Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71, 2005
51. Bellacosa A, de Feo D, Godwin AK, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285, 1995
52. Mitsiades CS, Mitsiades N, Koutsilieris M: The Akt pathway: Molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4:235-256, 2004
53. Knuefermann C, Lu Y, Liu B, et al: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212, 2003
54. Yuan ZQ, Feldman RI, Sussman GE, et al: AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: Implication of AKT2 in chemoresistance. J Biol Chem 278:23432-23440, 2003
55. Tsurutani J, West KA, Sayyah J, et al: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not 325 the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65:8423-8432, 2005
56. Yang L, Dan HC, Sun M, et al: Akt/Protein Kinase B Signaling Inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394-4399, 2004
57. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGFR signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
58. Apte SM, Fan D, Killion JJ, et al: Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10:897-908, 2004
59. Pietras K, Stumm M, Hubert M, et al: STI571 enhances the therapeutic index of epothilone by a tumor selective increase of drug uptake. Clin Cancer Res 9:3779-3787, 2003
60. Yanada M, Takeuchi J, Sugiura I, et al: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460-466, 2006
61. de Labarthe A, Rousselot P, Huguet-Rigal F, et al: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the GRAAPH-2003 study. Blood 109:1408-1413, 2007
62. Matei D, Emerson RE, Menning N, et al: Clinical activity of imatinib mesylate in combination with docetaxel in patients with advance platinum-resistant ovarian cancer- Hoosier Oncology Group GYN03-62. J Clin Oncol 24:278s, 2006 (suppl; abstr 5091)